Ibrance and Xtandi Could Be in the Top 10 Oncology Drugs by 2021



Top ten oncology drugs by 2021

Pfizer (PFE) won access to Medivation’s (MDVN) key drug Xtandi following the acquisition. Xtandi is the top-selling prostate cancer drug. It could become fourth best-selling oncology drug in the world. For more information on Xtandi, read Medivation Sees Growth in Xtandi: A Major Oncology Drug.

The two drugs in Pfizer’s oncology franchise will likely be among the top ten best-selling oncology drugs in the world by 2021. Ibrance is in its early growth phase. It was approved by the FDA in February 2015 to treat advanced breast cancer in postmenopausal women in combination with Letrozole.

Article continues below advertisement

Later in February 2016, it was approved for the treatment of HR+ (hormone receptor-positive), HER2- (human epidermal growth factor receptor 2-negative), metastatic breast cancer in combination with AstraZeneca’s (AZN) Faslodex in cases where the disease progressed after endocrine therapy. During the first six months of 2016, Ibrance earned $942 million. The drug’s expansion into an earlier line of therapies will result in higher penetration.

Competition in the oncology space

On August 3, 2016, Novartis’s (NVS) Ribociclib won breakthrough therapy designation following positive Phase III MONALEESA-2 trial results. If approved, the drug will compete with Ibrance.

Roche (RHHBY)—with its key oncology drugs Herceptin, Perjeta, Avastin, and Tecentriq—is one of the major oncology and immunology drug companies.

Investors should note that investing in any pharmaceutical or biotechnology company is very risky. To reduce direct equity risk, you can invest in the iShares Dow Jones US Healthcare ETF (IYH). The fund holds 7.2% of its assets in Pfizer.


More From Market Realist